Long lasting BCG protection against leprosy

Vaccine

Volumn 25, Issue 39-40, 2007, Pages 6842-6844

  Rodrigues, Laura Cunha ^a   Kerr Pontes, Ligia Regina Sansigolo ^b   Frietas, Max Victor Carioca ^b   Barreto, Maurício Lima ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^c FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

BCG vaccine; Duration of protection; Leprosy; Vaccine efficacy; Waning of protection

Indexed keywords

BCG VACCINE;

ADULT; ARTICLE; BCG VACCINATION; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; GROUPS BY AGE; HUMAN; INFECTION PREVENTION; INFECTION RISK; LEPROSY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK REDUCTION; SCAR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; BCG VACCINE; BRAZIL; CASE-CONTROL STUDIES; HUMANS; INCIDENCE; LEPROSY; MYCOBACTERIUM LEPRAE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME; VACCINATION;

EID: 34548593340     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.07.032     Document Type: Article

References (13)

1. http://dtr2001.saude.gov.br/svs/epi/hanseniase/hansen_00.htm.
2. Benevolo-de-Andrade T.C., Monteiro-Maia R., Cosgrove C., and Castello-Branco L.R. BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis-review. Mem Inst Oswaldo Cruz 100 5 (2005) 459-465
3. Sterne J.A., Rodrigues L.C., and Guedes I.N. Does the efficacy of BCG decline with time since vaccination?. Int J Tuberc Lung Dis 2 3 (1998) 200-207
4. Barreto M.L., Cunha S.S., Pereira S.M., Genser B., Hijjar M.A., Yury I.M., et al. Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil. Int J Tuberc Lung Dis 9 10 (2005) 1171-1173
5. Aronson N.E., Santosham M., Comstock G.W., Howard R.S., Moulton L.H., Rhoades E.R., et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA 291 17 (2004) 2086-2091
6. Zodpey S.P., Ambadekar N.N., and Thakur A. Effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of leprosy: a population-based case-control study in Yavatmal District, India. Public Health 119 3 (2005) 209-216
7. Kerr-Pontes L.R., Barreto M.L., Evangelista C.M., Rodrigues L.C., Heukelbach J., and Feldmeier H. Socioeconomic, environmental, and behavioural risk factors for leprosy in North-east Brazil: results of a case-control study. Int J Epidemiol (2006)
8. Pereira S.M., Dourado I., Barreto M.L., Cunha S.S., Ichiara M.Y., Hijjar M.A., et al. Sensitivity and specificity of BCG scar reading in Brazil. Int J Tuberc Lung Dis 5 11 (2001) 1067-1070
9. Cunha S.S., Rodrigues L.C., Pedrosa V., Dourado I.M., Barreto M.L., and Pereira S.M. Neonatal BCG protection against leprosy: a study in Manaus, Brazilian Amazon. Leprosy Rev 75 4 (2004) 357-366
10. Rodrigues M.L., Silva S.A., Neto J.C., de Andrade A.L., Martelli C.M., and Zicker F. Protective effect of intradermal BCG against leprosy; a case-control study in central Brazil. Int J Leprosy Other Mycobact Dis 60 3 (1992) 335-339
11. Lombardi C., Pedrazzani E.S., Pedrazzani J.C., Filho P.F., and Zicker F. Protective efficacy of BCG against leprosy in Sao Paulo. Bull Pan Am Health Organ 30 1 (1996) 24-30
12. Prelog M. Aging of the immune system: a risk factor for autoimmunity?. Autoimmun Rev 5 2 (2006) 136-139
13. Dantas O.M., Ximenes R.A., de Albuquerque M.deF., Montarroyos U.R., de Souza W.V., Varejao P., et al. Selection bias: neighbourhood controls and controls selected from those presenting to a Health Unit in a case control study of efficacy of BCG revaccination. BMC Med Res Methodol 7 (2007) 11